Cancer Therapy

Ceplene 36-month malignant melanoma survival data published

Published in Drug Week, July 2nd, 2004

Maxim Pharmaceuticals, Inc., (MAXM) announced that the 36-month patient follow-up data from the M01 phase III study of Ceplene (histamine dihydrochloride) as a combination therapy to treat advanced metastatic melanoma has been published electronically.

The 36-month results demonstrate the intent-to-treat population of all 305 advanced metastatic melanoma patients randomized into the trial demonstrated a statistically significant improvement in survival for patients treated with the combination of Ceplene and IL-2 (p=0.037, evaluated by comparing Kaplan-Meier survival curves using the log-rank test) compared to patients treated with IL-2 alone. The improvement in 3-year...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-07-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry